Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors

Glenmark Pharmaceuticals USA to launch Potassium Phosphates Injection USP in multiple vial sizes

The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk

Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer

The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts

Cbio launches first-in-human trial for groundbreaking cervical cancer therapy

GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes

This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin

Zuellig Pharma expands Cialis footprint across Asia

The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH

Finerenone hits major goal in Phase III FIND-CKD trial

There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk